New Transparent AI Predicts Breast Cancer 5 Years Out New Transparent AI Predicts Breast Cancer 5 Years Out
The model ' s easier-to-understand process marks an important milestone in the quest to bring AI to bedside in a meaningful way.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 21, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Myeloma: FDA Advisers Greenlight Early CAR-T Myeloma: FDA Advisers Greenlight Early CAR-T
An FDA advisory panel endorsed earlier use of CAR-T therapies to treat multiple myeloma but emphasized the importance of informing patients about potential risks associated with these treatments.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 21, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves Ponatinib for Upfront Ph+ ALL FDA Approves Ponatinib for Upfront Ph+ ALL
This is the first targeted treatment approved for upfront use in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 20, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Can ChatGPT Help Manage Gynecologic Cancers? Can ChatGPT Help Manage Gynecologic Cancers?
ChatGPT accurately answers common questions regarding gynecologic cancers but falls short in providing treatment recommendations, two separate studies found.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 19, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

De-escalating Therapy for Oropharynx Squamous Cell Carcinoma De-escalating Therapy for Oropharynx Squamous Cell Carcinoma
Three new studies exploring treatment de-escalation of HPV-associated oropharynx squamous cell carcinoma added to data showing it ' s possible to reduce toxicity without jeopardizing oncologic outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 19, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

RUBY:'A Huge Win' for Patients With Endometrial Cancer RUBY:'A Huge Win' for Patients With Endometrial Cancer
The RUBY trial shows that adding an immune checkpoint inhibitor to chemotherapy improved overall survival by over 1 year for women with advanced or recurrent endometrial cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 19, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

QOL Not Harmed With Add-On Pembrolizumab in Cervical Cancer QOL Not Harmed With Add-On Pembrolizumab in Cervical Cancer
Adding pembrolizumab to concurrent chemoradiotherapy does not affect quality of life in patients with high-risk locally advanced cervical cancer, new data show.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 18, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

EPA to Ban Last Form Of Asbestos Used in US EPA to Ban Last Form Of Asbestos Used in US
The U.S. Environmental Protection Agency on Monday finalized a rule that would ban using and importing cancer-causing asbestos, a material still used in some vehicles and in...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 18, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL
The accelerated approval for liso-cel was based on findings showing 20% of patients achieved a complete response from a one-time infusion after at least two prior lines of therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Customized Radiation of Uterus May Not Compromise Outcomes Customized Radiation of Uterus May Not Compromise Outcomes
Researchers found that patients with locally advanced cervical cancer who received less than whole uterus irradiation had low local recurrence rates and fewer side effects.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Gilead CAR-T Cancer Therapy Capacity to Quadruple by 2026 Gilead CAR-T Cancer Therapy Capacity to Quadruple by 2026
Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech ' s manufacturing processes, an...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves New Esophageal Cancer Drug FDA Approves New Esophageal Cancer Drug
The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Geron's Blood Disorder Drug Gets FDA Advisers' Backing Geron's Blood Disorder Drug Gets FDA Advisers' Backing
Advisers to the U.S. Food and Drug Administration on Thursday backed benefits of Geron ' s blood disorder drug, saying it outweighed the risks associated with the treatment,...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

In Memoriam: Drs Worta McCaskill-Stevens and Edith Mitchell In Memoriam: Drs Worta McCaskill-Stevens and Edith Mitchell
Dr Kathy Miller remembers two influential women in the breast cancer field, Dr Worta McCaskill-Stevens and Dr Edith Mitchell.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

No Benefit to Adding Chemotherapy in Older Adults With NSCLC No Benefit to Adding Chemotherapy in Older Adults With NSCLC
Adding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news